Issue 3/2013

  • Antibiotics from the ocean floor

    In this issue:

    Decades of antibiotic use and overuse have driven the evolution of a new generation of resistant superbugs. Because investing in antimicrobials usually brings a poor return, however, drug developers have not come up with replacement antibiotics for decades. Now experts are sounding the alarm. If nothing is done, infections that were once easy to treat could again become major killers in the next twenty years. Researchers now hope that help could come from the depths of the sea.

    Volume 2016

    Volume 2015

    Volume 2014

    Volume 2013

    Volume 2012

    © 2007-2016 BIOCOM


    Alle Kurse


    • NORDIC NANOVECTOR (N)31.90 NOK12.72%
    • VITA 34 (D)4.46 EUR5.69%
    • SAREUM HOLDINGS (UK)0.78 GBP5.41%


    • MOLOGEN (D)1.80 EUR-6.74%
    • GW PHARMACEUTICALS (UK)518.00 GBP-5.39%
    • DIAXONHIT (F)0.38 EUR-5.00%


    • DIAMYD MEDICAL -B- (S)7.20 SEK66.7%
    • KARO BIO (S)41.60 SEK35.1%
    • NORDIC NANOVECTOR (N)31.90 NOK30.7%


    • BIONOR PHARMA (N)0.44 NOK-25.4%
    • MOLOGEN (D)1.80 EUR-21.7%
    • WILEX (D)1.50 EUR-13.3%


    • NICOX (F)10.18 EUR435.8%
    • SAREUM HOLDINGS (UK)0.78 GBP254.5%
    • GENMAB (DK)1103.00 DKK80.8%


    • BB BIOTECH (D)45.05 EUR-83.2%
    • EVOCUTIS (UK)0.04 GBP-80.0%
    • CIRCASSIA LIMITED (L)92.75 GBP-71.7%

    No liability assumed, Date: 26.08.2016